Effects of intranasal oxytocin on emotion processing in frontotemporal dementia

The University of Sydney0 sites40 target enrollmentNovember 6, 2018

Overview

No summary available.

Registry

who.int

Start Date

November 6, 2018

End Date

TBD

Last Updated

3 years ago

Study Type

Interventional

Sex

All

Sponsor

•1\.Be within 40 to 75 years of age
•2\.Have a diagnosis of behavioural variant frontotemporal dementia, semantic dementia, or progressive non\-fluent aphasia
•3\.Have a carer who will be able to live with the participant during the study

•1\.Severely compromised cardiac, hepatic or renal function
•2\.Severe nasal obstruction/blockage
•3\.Sensitivity to preservatives (in particular benzyl alcohol 0\.9%), which are present in the nasal spray formulation
•4\.Upcoming surgery, due to concerns of interactions with other medications
•5\.Prior history of psychiatric disorders (e.g. major depression, schizophrenia, bipolar disorder)
•6\.Prescribed an anticholinesterase medication for less than three months or are experiencing side effects secondary to this class of medication.
•7\.Have prior history of neurological disorder other than dementia (e.g., head injury, stroke or transient ischemic attack, epilepsy)
•8\.Have a diagnosis of another neurodegenerative disease (e.g., Dementia with Lewy Bodies, Alzheimer’s Disease, Parkinson’ Disease)
•9\.Have an intellectual disability
•10\. Have a current history of substance abuse